Get the Stockscreener App
2.08
3.26%
-0.07
After Hours:
2.08
Immunitybio Inc stock is traded at $2.08, with a volume of 7.25M.
It is down -3.26% in the last 24 hours and down -15.79% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.15
Open:
$2.18
24h Volume:
7.25M
Relative Volume:
0.76
Market Cap:
$2.05B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.1443
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-0.95%
1M Performance:
-15.79%
6M Performance:
-17.79%
1Y Performance:
-58.73%
1-Day Range:
$2.05
$2.18
1-Week Range:
$2.01
$2.24
52-Week Range:
$1.83
$5.22
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.08 | 2.12B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Q3 2025 Contract Research Organization (CRO) Activity and Intel Report Featuring ICON, Astrazeneca, Akesobio, CSPPC Pharmaceutical, ImmunityBio, and Boryung - GlobeNewswire Inc.
H.C. Wainwright Asserts Buy Rating on Immunitybio Inc. (IBRX) as Net Loss Narrows on Robust Product Revenue - MSN
Can ImmunityBio Inc. (26CA) stock sustain free cash flow2025 Trading Volume Trends & Weekly High Potential Alerts - newser.com
Why analysts upgrade ImmunityBio Inc. stockMarket Risk Report & Consistent Income Trade Recommendations - newser.com
Intraday pattern recognizer results for ImmunityBio Inc.July 2025 Short Interest & Safe Capital Growth Trade Ideas - newser.com
How ImmunityBio Inc. (26CA) stock responds to bond marketWeekly Profit Summary & AI Driven Stock Price Forecasts - newser.com
Can ImmunityBio Inc. (26CA) stock test all time highsJuly 2025 Summary & Daily Technical Stock Forecast Reports - newser.com
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know - AOL.com
Will ImmunityBio Inc. (26CA) stock extend growth storyRate Hike & Verified Chart Pattern Signals - newser.com
Biotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock Move - MSN
Why ImmunityBio Inc. (26CA) stock is a strong analyst pickInsider Selling & Stock Portfolio Risk Management - newser.com
What dividend safety rating applies to ImmunityBio Inc. (26CA) stockMarket Trend Review & Weekly Hot Stock Watchlists - newser.com
Is ImmunityBio Inc. (26CA) stock a buy before earnings resultsPortfolio Update Report & Free Daily Entry Point Trade Alerts - newser.com
ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech (NASDAQ:IBRX) - Seeking Alpha
Is ImmunityBio Inc. (26CA) stock a safe buy pre earnings2025 Support & Resistance & Daily Oversold Bounce Ideas - newser.com
Applying big data sentiment scoring on ImmunityBio Inc.Trade Signal Summary & Safe Capital Allocation Plans - newser.com
Why ImmunityBio Inc. (26CA) stock is upgraded to buyAnalyst Upgrade & Momentum Based Trading Signals - newser.com
Editor: 【Stock Selection Techniques】 - newser.com
Will ImmunityBio Inc. (26CA) stock justify high valuation2025 Fundamental Recap & Weekly High Momentum Picks - newser.com
How ImmunityBio Inc. (26CA) stock compares with tech leadersJuly 2025 Selloffs & Free Real-Time Volume Trigger Notifications - newser.com
ImmunityBio : Jefferies Global Healthcare Conference in London - MarketScreener
Why retail investors favor ImmunityBio Inc. stockJuly 2025 Pullbacks & Free Growth Oriented Trading Recommendations - newser.com
What drives ImmunityBio Inc 26CA stock priceStock Split Announcements & Exceptional Return Stocks - earlytimes.in
ImmunityBio Inc. recovery potential after sell offJuly 2025 Drop Watch & Fast Entry High Yield Stock Tips - newser.com
Tick level data insight on ImmunityBio Inc. volatilityTrade Analysis Summary & Technical Confirmation Trade Alerts - newser.com
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):